Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
SM1
MCID: SCH060
MIFTS: 38

Schistosoma Mansoni Infection, Susceptibility/ (SM1)

Categories: Infectious diseases, Rare diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Schistosoma Mansoni Infection, Susceptibility/

About this section

MalaCards integrated aliases for Schistosoma Mansoni Infection, Susceptibility/:

Name: Schistosoma Mansoni Infection, Susceptibility/ 57
Schistosoma Mansoni Infection, Susceptibility/resistance to 57 13
Schistosomiasis 58 71
Sm1 57 17
Schistosoma Mansoni, Intensity of Infection by; Sm1 57
Schistosoma Mansoni, Intensity of Infection by 57
Bilharziasis 58

Characteristics:

Orphanet epidemiological data:

58
schistosomiasis
Inheritance: Not applicable; Age of onset: All ages;

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
autosomal dominant


HPO:

31
schistosoma mansoni infection, susceptibility/:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Infectious diseases Rare diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare infectious diseases


External Ids:

OMIM® 57 181460
MESH via Orphanet 45 D012552
ICD10 via Orphanet 33 B65.0 B65.1 B65.2 more
UMLS via Orphanet 72 C0036323
Orphanet 58 ORPHA1247
MedGen 41 C1866993
SNOMED-CT via HPO 68 263681008
UMLS 71 C0036323
Sources

Summaries for Schistosoma Mansoni Infection, Susceptibility/

About this section
MalaCards based summary : Schistosoma Mansoni Infection, Susceptibility/, also known as schistosoma mansoni infection, susceptibility/resistance to, is related to schistosomiasis and intestinal schistosomiasis. An important gene associated with Schistosoma Mansoni Infection, Susceptibility/ is SM1 (Schistosoma Mansoni, Susceptibility/Resistance To). The drugs Albendazole and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include liver, spinal cord and skin, and related phenotype is abnormality of the immune system.

More information from OMIM: 181460
Sources

Related Diseases for Schistosoma Mansoni Infection, Susceptibility/

About this section

Diseases related to Schistosoma Mansoni Infection, Susceptibility/ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 580)
# Related Disease Score Top Affiliating Genes
1 schistosomiasis 12.0
2 intestinal schistosomiasis 11.8
3 urinary schistosomiasis 11.7
4 cercarial dermatitis 11.3
5 pulmonary arterial hypertension associated with schistosomiasis 11.2
6 neuroschistosomiasis 11.1
7 hepatic fibrosis, severe due to schistosoma mansoni infection 10.9
8 portal hypertension 10.8
9 splenomegaly 10.8
10 varicose veins 10.7
11 hypereosinophilic syndrome 10.6
12 parasitic helminthiasis infectious disease 10.6
13 liver cirrhosis 10.6
14 fibrosis of extraocular muscles, congenital, 1 10.6
15 bladder cancer 10.6
16 esophageal varix 10.5
17 pulmonary hypertension 10.5
18 malaria 10.5
19 diarrhea 10.5
20 filariasis 10.5
21 proteinuria, chronic benign 10.4
22 allergic disease 10.4
23 appendicitis 10.4
24 fascioliasis 10.4
25 disease by infectious agent 10.4
26 pulmonary hypertension, primary, 1 10.4
27 paragonimiasis 10.4
28 viral hepatitis 10.4
29 myelitis 10.3
30 ancylostomiasis 10.3
31 filarial elephantiasis 10.3
32 clonorchiasis 10.3
33 liver disease 10.3
34 cytokine deficiency 10.3
35 hepatitis b 10.3
36 urinary tract obstruction 10.3
37 hydronephrosis 10.3
38 onchocerciasis 10.3
39 cystitis 10.3
40 hepatitis c 10.3
41 glomerulonephritis 10.3
42 transverse myelitis 10.3
43 strongyloidiasis 10.3
44 infertility 10.3
45 kala-azar 1 10.3
46 leishmaniasis 10.3
47 salmonellosis 10.3
48 hypersplenism 10.3
49 hepatitis c virus 10.2
50 portal vein thrombosis 10.2

Graphical network of the top 20 diseases related to Schistosoma Mansoni Infection, Susceptibility/:



Diseases related to Schistosoma Mansoni Infection, Susceptibility/
Sources

Symptoms & Phenotypes for Schistosoma Mansoni Infection, Susceptibility/

About this section

Human phenotypes related to Schistosoma Mansoni Infection, Susceptibility/:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of the immune system 31 HP:0002715

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Immunology:
schistosoma mansoni infection susceptibility/resistance

Clinical features from OMIM®:

181460 (Updated 05-Mar-2021)

Sources

Drugs & Therapeutics for Schistosoma Mansoni Infection, Susceptibility/

About this section

Drugs for Schistosoma Mansoni Infection, Susceptibility/ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Albendazole Approved, Vet_approved Phase 3 54965-21-8 2082
2
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
3
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
4
Triclabendazole Approved, Investigational Phase 3 68786-66-3
5
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
6
Mefloquine Approved, Investigational Phase 3 53230-10-7 4046
7
Artesunate Approved, Investigational Phase 3 88495-63-0 6917864 5464098
8
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
9
Piperaquine Experimental, Investigational Phase 3 4085-31-8 5079497
10 Antimitotic Agents Phase 3
11 Tubulin Modulators Phase 3
12 Folic Acid Antagonists Phase 3
13 Vitamin B Complex Phase 3
14 Folate Phase 3
15 Fanasil, pyrimethamine drug combination Phase 3
16 Vitamin B9 Phase 3
17 Antiprotozoal Agents Phase 3
18 Antimalarials Phase 3
19 Antiviral Agents Phase 3
20
Artemether Approved Phase 2 71963-77-4 119380 9796294 68911
21
Lumefantrine Approved Phase 2 82186-77-4 6437380
22
Epoprostenol Approved Phase 2 61849-14-7, 35121-78-9 5280427 5282411
23
Selexipag Approved Phase 2 475086-01-2
24
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
25
Pyronaridine Investigational Phase 2 74847-35-1 5485198
26 Tezosentan Investigational Phase 2 180384-57-0
27
Imidazole Experimental, Investigational Phase 1, Phase 2 288-32-4 795
28 Artemisinine Phase 2
29 Artemisinins Phase 2
30 Artemether, Lumefantrine Drug Combination Phase 2
31 Ferroquine Phase 2
32 Antihypertensive Agents Phase 2
33 Vaccines Phase 1, Phase 2
34 Gastrointestinal Agents Phase 1, Phase 2
35 Immunologic Factors Phase 1, Phase 2
36 Antacids Phase 1, Phase 2
37 Adjuvants, Immunologic Phase 1, Phase 2
38 Anti-Ulcer Agents Phase 1, Phase 2
39 Pharmaceutical Solutions Phase 1, Phase 2
40
Aluminum sulfate Approved Phase 1 10043-01-3
41 Immunoglobulins Phase 1
42 Antibodies Phase 1
43
Sodium citrate Approved, Investigational 68-04-2
44 Mango Approved
45
Iron Approved 7439-89-6 23925 29936
46
Ethanolamine oleate Approved 2272-11-9
47
Cefuroxime Approved 55268-75-2 5361202 5479529
48
Doxycycline Approved, Investigational, Vet_approved 564-25-0 54671203
49
Ciprofloxacin Approved, Investigational 85721-33-1 2764
50
Metronidazole Approved 443-48-1 4173

Interventional clinical trials:

(show top 50) (show all 61)
# Name Status NCT ID Phase Drugs
1 The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
2 Effect of Schistosomiasis Mansoni and Its Treatment on HIV Susceptibility and Female Genital Immunology Completed NCT02878564 Phase 4 Praziquantel
3 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Highly Endemic Areas of Northeastern Brazil Completed NCT00403611 Phase 4 Praziquantel 60 mg/kg;Praziquantel 40 mg/kg
4 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study Withdrawn NCT02734186 Phase 4 Praziquantel
5 Efficacy of Chinese-made Versus WHO-PQ Praziquantel for Treatment of Schistosoma Haematobium in Zanzibar: a Randomized Controlled Trial Unknown status NCT03133832 Phase 3 Companion Tablet
6 Efficacy and Safety of Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine Regimens Delivered Through Intermittent Preventive Treatment in Schoolchildren of Democratic Republic of Congo: A Randomised Control Trial Completed NCT01722539 Phase 3 Sulfadoxine-pyrimethamine;Piperaquine;Albendazole;Praziquantel
7 Safety and Efficacy of Mirazid for Schistosomiasis Treatment as Compared to Praziquantel: An Open-label Randomized Non-placebo-Controlled Study Completed NCT01529710 Phase 3 Myrrh
8 Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST): An Open Label, Randomized Controlled Trial of Single vs. Multiple Treatments of Praziquantel in Intestinal African Schistosomiasis in Côte d'Ivoire Completed NCT02868385 Phase 3 4x Praziquantel;1x Praziquantel
9 Schistosoma Haematobium Infections Among Schoolchildren in Central Sudan One Year After Treatment With Praziquantel Completed NCT01558336 Phase 3 praziquantel
10 Efficacy and Safety Evaluation of the Therapeutic Vaccine Candidate Sh28GST in Association With Praziquantel (PZQ) for Prevention of Clinical and Parasitological Recurrences of S. Haematobium Infection in Children Completed NCT00870649 Phase 3
11 Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study Completed NCT04115072 Phase 2, Phase 3 Praziquantel 600Mg Oral Tablet x 5;Praziquantel 600Mg Oral Tablet x 1
12 Prospective, Observational Study to Assess the Performance of CAA Measurement as a Diagnostic Tool for the Detection of Schistosoma Haematobium Infections in Pregnant Women and Their Newborn and Child in Lambaréné, Gabon Recruiting NCT03779347 Phase 3 Praziquantel
13 An Open Label, Phase III Efficacy and Safety Study of L Praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children 3 Months to 6 Years of Age, Including a 2:1 Randomized, Controlled Cohort of Schistosoma Mansoni Infected Children 4 to 6 Years of Age Treated With L PZQ ODT or Commercial PZQ (Biltricide®) Recruiting NCT03845140 Phase 3 L-PZQ ODT;Biltricide®;L-PZQ ODT
14 A Proof-of-concept Trial to Evaluate Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children Active, not recruiting NCT03893097 Phase 3 Praziquantel;Artesunate + Mefloquine
15 Activity of Mefloquine Against Urinary Schistosomiasis Completed NCT01132248 Phase 2 Mefloquine;S/P
16 Evaluation of the Effect of Artemisinin-based Combination Therapies on Urinary Schistosoma Haematobium When Administered for the Treatment of Malaria Co-infection Completed NCT04264130 Phase 2 Artesunate-Pyronaridine;Artemether-Lumefantrine;Artefenomel-Ferroquine
17 Intestinal Schistosomiasis in Children Aged 1-5 Years,Morbidity Assessment and the Effect of Praziquantel on Morbidity; Along Lake Victoria Shorelines. Completed NCT01901484 Phase 2 Praziquantel
18 Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 Against Schistosomiasis in Senegalese School Children Healthy or Infected With S. Mansoni and/or S. Haematobium. A Comparative, Randomized, Controlled, Open-label Trial Completed NCT03799510 Phase 2 GLA-SE solution
19 Open-label, Dose-finding, 2-parts, Efficacy Phase II Study With Three Formulations (Racemate Raziquantel Commercial Oral Tablets, New Oral Disintegrating Tablets of Racemate Praziquantel and L-praziquantel) in Schistosomiasis (S. Mansoni) Infected Children Aged 2-6 Years (Part 1), Followed by an Assessment of Efficacy and Safety With the Selected Formulation and Dosage in S. Mansoni Infected Infants Aged 3-24 Months (Part 2) Completed NCT02806232 Phase 2 Biltricide (racemate praziquantel) oral tablets;Racemate Praziquantel ODT;Levo Praziquantel ODT
20 S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT) Completed NCT00486863 Phase 2 Praziquantel
21 Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 in Combination With the Adjuvant Glucopyranosyl Lipid A (GLA-SE) in Adults Living in Endemic Regions for S. Mansoni and S. Haematobium in Senegal. A Comparative, Randomized, Open-label Trial Completed NCT03041766 Phase 2 GLA-SE solution
22 Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension Recruiting NCT04589390 Phase 2 Selexipag
23 A Phase I/II Trial of the Safety, Immunogenicity, and Efficacy of the Sm-TSP-2/Alhydrogel® Schistosomiasis Vaccine in Healthy Exposed Ugandan Adults Recruiting NCT03910972 Phase 1, Phase 2
24 Phase II PK/PD Driven Dose Finding Trial of Praziquantel in Children Under Four Not yet recruiting NCT03640377 Phase 2 Praziquantel
25 Phase 1 Study Evaluating Safety and Immunological Criteria of Efficacy of the Recombinant Vaccine Candidate Bilhvax Against Schistosomiasis Completed NCT01512277 Phase 1
26 A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Completed NCT03110757 Phase 1
27 A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Completed NCT02337855 Phase 1
28 Phase 1 Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Completed NCT01154049 Phase 1
29 Praziquantel Pharmacokinetics in Pregnancy and During Lactation Completed NCT01288872 Phase 1 Praziquantel
30 Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Among School Children in Jinja District, Uganda: a Stratified Cluster Randomized Controlled Trial Unknown status NCT01869465
31 Epidemiology of Human Immunodeficiency Virus (HIV-1) and Schistosoma Mansoni Co-infections and Its Impact on Anthelminthic Treatment Outcome Among HIV-1 Infected Individuals in Fishing Communities in Mwanza Region, Northwestern Tanzania. Unknown status NCT01541631 Praziquantel and Albendazole;Praziquantel and Albendazole;Praziquantel and Albendazole
32 Association of Schistosomiasis Seropositivity With Adverse Birth Events in Migrants From Bilharzia-endemic Areas Unknown status NCT03158298
33 Study on the Role of Antioxidant Micronutrients on the Reversal of Schistosomal Peri-portal Fibrosis of the Liver. Unknown status NCT01260012
34 Women and Childres at the Focal Point for the Schistosomiasis Control and Sustainability and Effectiveness in the Hydro Agricultural Zone of Sourou, Burkina Faso Completed NCT00463528
35 Evaluation of Applicability of Urine Based Schistosomiasis Test Strip in the Epidemiologic Mapping and Sampling of Schistosoma Mansoni Infection in Low Endemic Areas of Kenya Completed NCT00463307
36 Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control Completed NCT00463632
37 Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Completed NCT00463593
38 Assessment of Anaemia Attributable to Schistosomiasis in School Children in Kenya: Mechanisms and Effect of Treatment Completed NCT00414479 praziquantl, iron, ACT
39 A Randomized Control Study to Evaluate Novel Interventions to Reduce Risk Factors Associated With HIV, Neglected Tropical and Non-communicable Diseases Among Couples in Zambia Completed NCT02744586
40 Village Surveys of Morbidity Due to S. Haematobium for 1U01AI4547 Urinary Schistosomiasis-Determinants of Infection and Disease Completed NCT00138450
41 Treatment of Schistosomal Portal Hypertension: Assessment of Efficacy of Endoscopic Therapy Alone or in the Combined With Surgical Procedure Completed NCT01931826
42 Study of Reproductive Health in Rural Madagascar With Emphasis on Urogenital Schistosomiasis and Sexually Transmitted Infections Completed NCT00713999 Treatment with anti-STI and anti-schistosoma regimens
43 Health Benefits of Repeated Treatment in Pediatric Schistosomiasis Completed NCT01424410
44 Establishing a Single-sex Controlled Human Schistosomiasis Infection Model: Safety and Dose Finding Completed NCT02755324
45 Effects of Arachidonic Acid Supplementation on Schistosomiasis Mansoni Infection in Egyptian School Children Completed NCT02144389 Praziquantel (PZQ)
46 Using Community-Based Volunteers to Reach Non-Enrolled School-Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana Completed NCT00463931
47 Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia Completed NCT00276224 ferrous sulphate (drug)
48 Comparison of Schistosomiasis Diagnostic Techniques and Study of Schistosoma Infection on Children's Immune Response to Childhood Vaccines, on Anaemia and on Nutritional Status Completed NCT01553552
49 Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment Completed NCT02495909
50 Detection of Schistosomiasis Circulating Anodic Antigen (CAA) in Travellers After High-risk Water Contact Completed NCT02194712

Search NIH Clinical Center for Schistosoma Mansoni Infection, Susceptibility/

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Praziquantel
Sources

Genetic Tests for Schistosoma Mansoni Infection, Susceptibility/

About this section
Sources

Anatomical Context for Schistosoma Mansoni Infection, Susceptibility/

About this section

MalaCards organs/tissues related to Schistosoma Mansoni Infection, Susceptibility/:

40
Liver, Spinal Cord, Skin, Spleen, T Cells, Colon, Lung
Sources

Publications for Schistosoma Mansoni Infection, Susceptibility/

About this section

Articles related to Schistosoma Mansoni Infection, Susceptibility/:

(show top 50) (show all 16666)
# Title Authors PMID Year
1
Severe hepatic fibrosis in Schistosoma mansoni infection is controlled by a major locus that is closely linked to the interferon-gamma receptor gene. 61 57
10441577 1999
2
Absence of linkage between MHC and a gene involved in susceptibility to human schistosomiasis. 57 61
9698772 1998
3
Genetic localization of a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. 57 61
8841190 1996
4
Evidence for the segregation of a major gene in human susceptibility/resistance to infection by Schistosoma mansoni. 61 57
1902058 1991
5
Schistosoma mansoni triggers Dectin-2, which activates the Nlrp3 inflammasome and alters adaptive immune responses. 57
21059925 2010
6
Schistosoma mansoni secretes a chemokine binding protein with antiinflammatory activity. 57
16301741 2005
7
Full results of the genome-wide scan which localises a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. 57
10094195 1999
8
Further evidence suggesting the presence of a locus, on human chromosome 5q31-q33, influencing the intensity of infection with Schistosoma mansoni. 57
9311752 1997
9
Circulating cell-free mitochondrial DNA fragment: A possible marker for early detection of Schistosoma japonicum. 61
33348056 2021
10
Effect of methyl gallate on immune response of Biomphalaria alexandrina (Ehrenberg, 1831) snails to infection with Schistosoma mansoni (Sambon, 1907). 61
33409634 2021
11
Hepatocyte CD1d protects against liver immunopathology in mice with schistosomiasis japonica. 61
33283278 2021
12
Pulmonary Vascular Diseases Associated with Infectious Disease-Schistosomiasis and Human Immunodeficiency Viruses. 61
33541618 2021
13
Use of Schistosoma mansoni soluble egg antigen (SEA) for antibody detection and diagnosis of schistosomiasis: The need for improved accuracy evaluations of diagnostic tools. 61
33352167 2021
14
Clinicopathologic Features of Chronic Intestinal Schistosomiasis and Its Distinction From Crohn Disease. 61
32991343 2021
15
Impact of seven years of mass drug administration and recrudescence of Schistosoma haematobium infections after one year of treatment gap in Zanzibar: Repeated cross-sectional studies. 61
33577601 2021
16
Characterization of class II fumarase from Schistosoma mansoni provides the molecular basis for selective inhibition. 61
33549669 2021
17
Optimization of Benzothiazole and Thiazole Hydrazones as Inhibitors of Schistosome BCL-2. 61
33523649 2021
18
Identifying and validating the presence of Guanine-Quadruplexes (G4) within the blood fluke parasite Schistosoma mansoni. 61
33600427 2021
19
The IL-33/ST2 pathway is not essential to Th2 stimulation but is key for modulation and survival during chronic infection with Schistosoma mansoni in mice. 61
33341001 2021
20
Radicicol, a Novel Lead Compound against the Migratory-Stage Schistosomula of Schistosoma japonicum. 61
33361311 2021
21
Population differences in vaccine responses (POPVAC): scientific rationale and cross-cutting analyses for three linked, randomised controlled trials assessing the role, reversibility and mediators of immunomodulation by chronic infections in the tropics. 61
33593767 2021
22
Modelling the present and future distribution of Biomphalaria species along the watershed of the Middle Paranapanema region, São Paulo, Brazil. 61
33227259 2021
23
STAT3 Promotes Schistosome-Induced Liver Injury by Inflammation, Oxidative Stress, Proliferation, and Apoptosis Signal Pathway. 61
33257536 2021
24
Factors Associated with Schistosoma mansoni Infestation in Northeast Brazil: A Need to Revisit Individual and Community Risk Factors. 61
33591939 2021
25
Prevalence of Schistosoma mansoni infection in Ethiopia: a systematic review and meta-analysis. 61
33522949 2021
26
Impact of Coinfection with Schistosoma mansoni on the Antibody Response to Helicobacter pylori. 61
33598776 2021
27
Delayed diagnosis of neuroschistosomiasis in a non-endemic country: A tertiary referral centre experience. 61
33571228 2021
28
Granuloma formation and tissue pathology in Schistosoma japonicum versus Schistosoma mansoni infections. 61
32692855 2021
29
Revisiting the Schistosoma japonicum life cycle transcriptome for new insights into lung schistosomula development. 61
33548219 2021
30
Activities of Quinoxaline, Nitroquinoxaline, and [1,2,4]Triazolo[4,3-a]quinoxaline Analogs of MMV007204 against Schistosoma mansoni. 61
33257453 2021
31
Gas chromatography-mass spectrometry (GC/MS) reveals urine metabolites associated to light and heavy infections by Schistosoma mansoni in mice. 61
33157242 2021
32
A critical assessment of proposed outbreaks of plague and other epidemic diseases in Ancient Egypt. 61
33227516 2021
33
Mycobacterium leprae-Helminth Co-Infections and Vitamin D Deficiency as Potential Risk Factors for Leprosy: A Case-Control Study in Southeastern Brazil. 61
33592342 2021
34
A Machine Learning Strategy for Drug Discovery Identifies Anti-Schistosomal Small Molecules. 61
33434015 2021
35
Polyparasitism with Schistosoma haematobium, Plasmodium and soil-transmitted helminths in school-aged children in Muyuka-Cameroon following implementation of control measures: a cross sectional study. 61
33597042 2021
36
Soil-transmitted helminths and schistosome infections in Ethiopia: a systematic review of progress in their control over the past 20 years. 61
33546757 2021
37
Characterization and localization of antigens for serodiagnosis of human paragonimiasis. 61
33415393 2021
38
Schistosome and intestinal helminth modulation of macrophage immunometabolism. 61
32614982 2021
39
Should obstetricians working in non-endemic countries care about emerging tropical diseases? 61
33359921 2021
40
Two Case Reports of Urinary Schistosomiasis in Adopted Children. 61
33165277 2021
41
Schistosomiasis is associated with rectal mucosal inflammation among Kenyan men who have sex with men. 61
33533314 2021
42
Portal vein thrombosis in patients with hepatosplenic schistosomiasis who underwent oesophagogastric devascularization combined with splenectomy. 61
33537723 2021
43
An Update on the Epidemiological Features of Imported Schistosomiasis and Cystic Echinococcosis in Kuwait, 2010-2018. 61
33524982 2021
44
Retraction Note: Knowledge, attitude and practices in relation to prevention and control of schistosomiasis infection in Mwea Kirinyaga county, Kenya. 61
33563236 2021
45
Low specificity of point-of-care circulating cathodic antigen (POC-CCA) diagnostic test in a non-endemic area for schistosomiasis mansoni in Brazil. 61
33587944 2021
46
Whole-proteome differential screening identifies novel vaccine candidates for schistosomiasis japonica. 61
33606021 2021
47
Latent Class Analysis: Insights about design and analysis of schistosomiasis diagnostic studies. 61
33539357 2021
48
Assessment of China's contributions to the Regional Network for Asian Schistosomiasis and Other Helminth Zoonoses: a questionnaire survey. 61
33597021 2021
49
Intestinal schistosomiasis among preschool and school-aged children in a rural setting near Alexandria: Initiative for elimination. 61
33576107 2021
50
Maternal schistosomiasis impairs offspring Interleukin-4 production and B cell expansion. 61
33524040 2021
Sources

Variations for Schistosoma Mansoni Infection, Susceptibility/

About this section
Sources

Expression for Schistosoma Mansoni Infection, Susceptibility/

About this section
Search GEO for disease gene expression data for Schistosoma Mansoni Infection, Susceptibility/.
Sources

Pathways for Schistosoma Mansoni Infection, Susceptibility/

About this section
Sources

GO Terms for Schistosoma Mansoni Infection, Susceptibility/

About this section
Sources

Sources for Schistosoma Mansoni Infection, Susceptibility/

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....